Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)

• 1. 病毒唑－聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法 [P] . 中国专利： CN1516599A . 2004-07-28
• 2. 灭除慢性丙型肝炎感染患者可检测的HCV－RNA的联合治疗 [P] . 中国专利： CN1250283C . 2006.04.12
• 3. Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV) [P] . 美国专利： US7671017B2 . 2010-03-02

  机译： 环孢素和聚乙二醇化干扰素联合治疗丙型肝炎（HCV）的用途

• 4. Use of a Combination of Cyclosporine and Pegylated Interferon for Treating Hepatitis C (Hcv) [P] . 美国专利： US2008138316A1 . 2008-06-12

  机译： 环孢素和聚乙二醇化干扰素联合治疗丙型肝炎（Hcv）的用途

• 5. USE OF A COMBINATION OF CYCLOSPORINE AND PEGYLATED INTERFERON FOR TREATING HEPATITIS C (HCV) [P] . 韩国专利： KR20070036175A . 2007-04-02

  机译： 环孢霉素和聚乙二醇化干扰素联合用于治疗丙型肝炎（HCV）

• 1. French Hepatitis C (HCV) Patients Treated with Anti-viral Combinations Containing Pegylated Interferon (IFN), Ribavirin (RBV), Sofosbuvir (SOF), Ledipasvir (LDV), Velpatasvir (VEL) and/or Voxilaprevir (VOX): The Impact of Treatment on Patient-Reported Outcomes (PROs) [J] . Cacoub Patrice P., Bourliere Marc, Asselah Tarik, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期
• 2. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. [J] . Le Pogam S, Seshaadri A, Ewing A, The Journal of Infectious Diseases . 2010,第10期
• 3. RG7128 Alone or in Combination with Pegylated Interferon-α2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV-Infected Patients [J] . Sophie Le Pogam, Amritha Seshaadri, Aren Ewing, Journal of Infectious Diseases . 2010,第10期
• 4. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus (HCV) infection treated with alpha-interferon [C] . S. GEHRING, E. LAUSCH, U. KULLMER, Falk Symposium . 2002
• 5. The meaning of adherence among veterans receiving pegylated interferon and ribavirin antiviral treatment for chronic hepatitis C. [D] . Phillips, Frances Hinshaw. 2011
• 6. Genetic Variability of Hepatitis C Virus (HCV) 5’ Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin [O] . Iwona Bukowska-Ośko, Agnieszka Pawełczyk, Karol Perlejewski, -1
• 7. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study [O] . Laguno M., Von Wichmann M.A., Van den Eynde E., 2016

• 1. Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents [J] . Giovanni Damiani ,Chiara Franchi ,Paolo Pigatto . 世界肝病学杂志：英文版（电子版） . 2018,第2期
• 2. Combination Therapy with Pegylated Interferon alpha-2b and Adefovir Dipivoxil in HBeAg-positive Chronic Hepatitis B versus Interferon Alone: A Prospective, Randomized Study [J] . Yu-hua LIU ,Tao WU ,Ning SUN . 华中科技大学学报（医学）（英德文版） . 2014,第004期
• 3. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children [J] . Suzan El Naghi ,Tawhida Y Abdel-Ghaffar ,Hanaa El-Karaksy . 世界胃肠病学杂志：英文版 . 2014,第16期
• 4. Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C [J] . Iman Zandieh ,Mohamed Adenwalla ,Cindy Cheong-Lee . 世界胃肠病学杂志：英文版 . 2006,第30期
• 5. liver Histopathological Features Influencing HBeag seroconversion in Patients with HBeag-positive Chronic Hepatitis B treated with Pegylated Interferonα [J] . Yao-ren Hu ,Hua-dong Yan ,Guo-sheng Gao . 国际感染杂志（电子版） . 2014,第001期
• 6. 不同感染途径的丙型肝炎患者血清HCV-RNA抗-HCV及ALT水平的分析 [C] . 赵友云 ,高应林 ,乐惠荣 . 第六次全国医学分子微生物学及生物技术研讨会 . 2006
• 7. 聚乙二醇化干扰素联合利巴韦林治疗肝移植术后丙型肝炎复发 [A] . 王平良 . 2013